• 1
    Kannel WB. Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA. 1996;275:15711576.
  • 2
    Whelton PK, He J, Perneger TV, et al. Kidney damage in “benign” essential hypertension. Curr Opin Nephrol Hypertens. 1997;6:177183.
  • 3
    Launer LJ, Masaki K, Petrovitch H, et al. The association between midlife blood pressure levels and late-life cognitive function: the Honolulu-Asia Aging Study. JAMA. 1995;274:18461851.
  • 4
    Ornstein SM, Nietert PJ, Dickerson LM. Hypertension management and control in primary care: a study of 20 practices in 14 states. Pharmacotherapy. 2004;24(4):500507.
  • 5
    Zicha J, Kunes J, Devynck M, et al. Abnormalities of membrane function and lipid metabolism in hypertension. Am J Hypertens. 1999;12:315331.
  • 6
    Assmann G, Schulte H, Cullen P. New and classical risk factor: the Munster heart study (PROCAM). Eur J Med Res. 1997;2:237242.
  • 7
    Kannel WB. Cardioprotection and antihypertensive therapy: the key importance of addressing the associated coronary risk factors. Am J Cardiol. 1996;77:6B11B.
  • 8
    Flack JM, Neaton J, Grimm R, et al. Blood pressure and mortality among men with prior myocardial infarction: Multiple Risk Factor Investigation Trial Research Group (MR-FIT). Circulation. 1995;92:24372445.
  • 9
    Castelli WP, Anderson K. A population at risk. Prevalence of high cholesterol levels in hypertensive patients in the Framingham Study. Am J Med. 1986;80:2332.
  • 10
    Sica DA. Combination calcium channel blocker therapy in the treatment of hypertension. J Clin Hypertens (Greenwich). 2001;3(5):322327.
  • 11
    Verhaar MC, Honing ML, Dam TV, et al. Nifedipine improves endothelial function in hypercholestrolemia independently of an effect on blood pressure or plasma lipids. Cardiovasc Res. 1999;42:752760.
  • 12
    Sinai CJ, Frank JC, Gonzalez FJ, et al. Guggulsterone: an old approach to a new problem. Trends Endocrinol Metab. 2002;13(7):275276.
  • 13
    Urizar NL, Moore DD. Guggulipid: a natural cholesterol-lowering agent. Annu Rev Nutr. 2003;23:303313.
  • 14
    Satyavati GV. Gum guggul (Commiphora mukul)—the success story of an ancient insight leading to a modern discovery. Indian J Med Res. 1988;87:327335.
  • 15
    Satyavati GV. Guggulipid: a promising hypolipidaemic agent from gum guggul (Commiphora mukul). In: WagnerH, FarnsworthNR, eds. Economic and Medicinal Plant Research Vol 5. Plants and Traditional Medicine. New York, NY: Academic Press; 1991:4782.
  • 16
    Verma SK, Bordia A. Effect of Commiphora mukul (gum guggulu) in patients of hyperlipidemia with special reference to HDL-cholesterol. Indian J Med Res. 1988;87:356360.
  • 17
    Folch J, Lees M, Stanley GHS. A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem. 1957;226:497502.
  • 18
    Falholt K, Falholt W, Lund B. An easy colorimetric method for routine determination of free fatty acids in plasma. Clin Chim Acta. 1973;46:105111.
  • 19
    Stewart JC. Colorimetric determination of phospholipids with ammonium ferrothiocyanate. Anal Biochem. 1980;104:1014.
  • 20
    Papadakis JA, Ganotakis ES, Jagroop IA, et al. Effect of hypertension and its treatment on lipids, lipoprotein(a), fibrinogen, and bilirubin levels in patients referred for dyslipidemia. Am J Hypertens. 1999;12:673681.
  • 21
    Dey HM, Soufer R, Hoffer P, et al. Comparison of nifedipine GITS and hydrochlorothiazide in the management of elderly patients with stage I–III diastolic hypertension. Am J Hypertens. 1996;9:589606.
  • 22
    Kostis JB. Treatment of hypertension in older patients: an updated look at the role of calcium antagonists. Am J Geriatr Cardiol. 2003;12:319327
  • 23
    Muntwyler J, Follath F. Calcium channel blockers in treatment of hypertension. Prog Cardiovasc Dis. 2001;44:207216.
  • 24
    Martin MJ, Hulley SB, Browner WS, et al. Serum cholesterol, blood pressure, and mortality: implications from a cohort of 361,662 men. Lancet. 1986;2:933936.
  • 25
    Lakshman MR, Reda D, Materson BJ, et al. Comparison of plasma lipid and lipoprotein profiles in hypertensive black versus white men. Am J Cardiol. 1996;78:12361241.
  • 26
    Block LH, Matthys H, Emmons LR, et al. Ca2+-channel blockers modulate expression of 3-hydroxy-3-methylglutaryl Coenzyme-A reductase and low density lipoprotein receptor genes stimulated by platelet-derived growth factor. Proc Natl Acad Sci USA. 1991;88:90419045.
  • 27
    Ryomoto KI, Suzuki M, Kanazava A, et al. Hyperapobet alipoproteinemia with compositional abnormality of LDL and HDL, a characteristic lipoprotein alteration in essential hypertension. Am J Hypertens. 2000;13:617624.
  • 28
    Ferrannini E, Natali A. Essential hypertension, metabolic disorders and insulin resistance. Am Heart J. 1991;121:12741282.
  • 29
    Tobey TA, Greenfield M, Kraemer F, et al. Relationship between insulin resistances, insulin secretion, very low density lipoprotein kinetics and plasma triglyceride levels in normoglyceridemic man. Metabolism. 1981;30:165171.
  • 30
    Bruce R, Godsland I, Walton C, et al. Association between insulin sensitivity and free fatty acid and triglyceride metabolism independent of uncomplicated obesity. Metabolism. 1994;43:12751281.
  • 31
    Lemne C, Hamsten A, Karfe F, et al. Dyslipoproteinemic changes in borderline hypertension. Hypertension. 1994;24:605610.
  • 32
    Stochmal A, Goldsztajn P, Hartwich M, et al. Very low density lipoprotein composition an endogenous insulin response in primary hypertension. J Hypertens Suppl. 1993;11(suppl 5):S278S279.
  • 33
    Pierdomenico SD, Costantini F, Bucci K, et al. Low-density lipoprotein oxidation and vitamin E and C in sustained and white-coat hypertension. Hypertension. 1998;31:621626.
  • 34
    Laakso M, Sarlund H, Mykkanen L. Insulin resistance is associated with lipid and lipoprotein abnormalities in subjects with varying degrees of glucose tolerance. Arteriosclerosis. 1990;10:223231.
  • 35
    Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities—the role of insulin resistance and the sympathoadrenal system. N Engl J Med. 1996;334:374381.
  • 36
    Horio T, Miyazoto J, Kamide K, et al. Influence of low high-density lipoprotein cholesterol on left ventricular hypertrophy and diastolic function in essential hypertension. Am J Hypertens. 2003;16:938944.
  • 37
    Manninen V, Tenkanen L, Koskinen P, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: implications for treatment. Circulation. 1992;85:3745.
  • 38
    Szapary PO, Wolfe ML, Bloedon LT, et al. Guggulipid for the treatment of the treatment of hypercholesterolemia: a randomized controlled trial. JAMA. 2003;290:765772.